Tandem t:slim X2 pump
Selected indexed studies
- Safety and Psychological Outcomes of Tandem t:Slim X2 Insulin Pump with Control-IQ Technology in Children, Adolescents, and Young Adults with Type 1 Diabetes: A Systematic Review. (Diabetes Ther, 2024) [PMID:39008237]
- An overview of the t:slim X2 and Mobi insulin pumps with Control-IQ technology: patient safety and device efficacy. (Expert Rev Med Devices, 2025) [PMID:41175172]
- Smartphone Bolus Feature Increases Number of Insulin Boluses in People With Low Bolus Frequency. (J Diabetes Sci Technol, 2024) [PMID:37605474]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Safety and Psychological Outcomes of Tandem t:Slim X2 Insulin Pump with Control-IQ Technology in Children, Adolescents, and Young Adults with Type 1 Diabetes: A Systematic Review. (2024) pubmed
- An overview of the t:slim X2 and Mobi insulin pumps with Control-IQ technology: patient safety and device efficacy. (2025) pubmed
- Smartphone Bolus Feature Increases Number of Insulin Boluses in People With Low Bolus Frequency. (2024) pubmed
- Control-IQ Technology Provides Similar Glycemic Outcomes Across Two Different CGM Sensors. (2025) pubmed
- Safety and Feasibility Evaluation of Automated User Profile Settings Initialization and Adaptation With Control-IQ Technology. (2024) pubmed
- Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial. (2024) pubmed
- Cost-Utility Analysis of Control-IQ Technology Relative to Conventional Insulin Therapy in Adults with Type 1 Diabetes. (2026) pubmed
- Consistent Benefit of Control-IQ+ Automated Insulin Delivery Across a Range of Characteristics of Adults with Type 2 Diabetes. (2026) pubmed